BFM
WHWK

Boothbay Fund Management’s Whitehawk Therapeutics WHWK Stock Holding History

Boothbay Fund Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12,721
Closed -$157K – 2666
2022
Q2 		$157K Sell
12,721
-43,319
-77% -$643K ﹤0.01% 1855
2022
Q1 		$427K Buy
56,040
+31,088
+125% +$596K 0.01% 1390
2021
Q4 		$603K Buy
+24,952
New +$627K 0.01% 939
2021
Q3 		– Sell
-13,912
Closed -$353K – 2248
2021
Q2 		$353K Sell
13,912
-6,285
-31% -$144K 0.01% 1185
2021
Q1 		$391K Buy
20,197
+16,851
+504% +$388K 0.01% 1073
2020
Q4 		$49K Sell
3,346
-24,382
-88% -$521K ﹤0.01% 1195
2020
Q3 		$624K Buy
+27,728
New +$583K 0.04% 578

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Boothbay Fund Management's WHWK Position: Q3 2022 in Review

Boothbay Fund Management sold out of Whitehawk Therapeutics (WHWK) in Q3 2022, closing a stake of 12,721 shares — an estimated $157K sold.

Boothbay Fund Management first reported a position in WHWK in Q3 2020 and held it in 7 quarters. The position peaked at $624K in Q3 2020. 68 funds tracked by Wall St. Rank hold WHWK as of Q3 2022.

  • Boothbay Fund Management reported no remaining Whitehawk Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 12,721 Whitehawk Therapeutics shares in Q3 2022, an estimated $157K.
  • Boothbay Fund Management first reported a position in Whitehawk Therapeutics in Q3 2020 and held it in 7 quarters.
  • Boothbay Fund Management's Whitehawk Therapeutics position peaked at $624K in Q3 2020.
  • 68 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.